MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor-positive HER2-negative breast cancer. Cai Y, Liu CC, Zhang Y, Liu Y, et al. J Clin Invest 2024 Nov 12:e183656. doi: 10.1172/JCI183656.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Cai Y, Liu CC, Zhang Y, Liu Y, et al. MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor-positive HER2-negative breast cancer. J Clin Invest 2024 Nov 12:e183656. doi: 10.1172/JCI183656.
PMID: 39531335